Podcast Summary: "What's Your Problem?"

Episode: Growing New Livers to Save Lives
Date: March 19, 2026
Host: Jacob Goldstein
Guest: Dr. Michael Hufford, CEO & Co-Founder of LyGenesis

Episode Overview

In this episode, Jacob Goldstein speaks with Dr. Michael Hufford, the CEO and co-founder of LyGenesis, a company at the forefront of regenerative medicine. LyGenesis is developing a pioneering treatment for end-stage liver disease: by injecting healthy liver cells into a patient’s lymph nodes, patients can potentially "grow" new, functioning mini-livers within their bodies. The episode delves into the science behind this innovation, the limitations of current organ transplantation, the challenges and unknowns of this therapy, and the broader future of regenerative medicine.

Key Discussion Points & Insights

1. The Liver and Why It Matters

• Regeneration Unique to the Liver
  Michael Hufford: “It is remarkable because it's the only organ in the human body that will naturally regenerate. So you can lose 70% of your liver, and over a course of just a few weeks, you will regenerate that liver entirely. And that's true only for the liver.” (03:50)
• Historical Awareness
  The myth of Prometheus from Greek mythology serves as an ancient nod to the liver’s regenerative ability. The Greeks seemed to recognize this unique biology (04:40).

2. The Challenges with Liver Transplantation

• Demand vs. Supply
  • Roughly 9,000 people in the US are waiting for a liver transplant annually, but 15–20% will die while waiting due to lack of available organs, and only a fraction of those who need a transplant qualify for the procedure (06:14).
• Transplant Limitations
  • “You have about 5 million cases of end stage liver disease… 85,000 deaths. At least 50%… don't qualify [for transplant] because we know that they simply won't survive the procedure because it's a big open surgery that involves a lot of trauma and if you're very sick already, you'll probably die from the surgery.” (06:47)

3. The Science Behind LyGenesis: Growing New Livers

• Origins of the Technology
  • Dr. Hufford was introduced to Dr. Eric Lagasse’s research demonstrating that donor liver cells injected into lymph nodes of mice with liver disease could essentially grow mini-livers and rescue the mice (08:06, 09:47).
• Ectopic Organs in Lymph Nodes
  • “The lymph node acts as a temporary bioreactor to get that ectopic organ… And those ectopic livers in mice could grow to 70% the size of a normal liver…” (10:19)
• Large Animal Models
  • This approach was also shown to work in pigs, leading to life-saving effects in those models and tremendous excitement about the robustness of the results (13:58).
  • Notable Quote:
    “He told me something that as a drug developer, you, you virtually never hear. He said, ‘Michael, I can't get this not to work.’” (14:08)

4. How the Therapy Works in Humans

• Current Clinical Trial Status
  • LyGenesis is conducting a Phase 2a human clinical trial for patients with end-stage liver disease, where donor liver cells are injected into a patient’s lymph node via endoscopic ultrasound (16:09).
  • The goal: even a 10–20% improvement in liver function could be transformative for patient outcomes (23:06).
• The Procedure
  • Donor livers unusable for transplant are processed to extract hepatocytes, which are then suspended in a liquid and transplanted into the lymph node through a minimally invasive procedure (19:24–21:27).

5. Why It Works (and the Central Mystery)

• Lymph Node as a Bioreactor
  • Lymph nodes are evolutionarily designed to “grow” immune cells but, when injected with hepatocytes, “are remarkably agnostic about the type of tissue they ‘bioreact’” (11:55, 30:26).
  • “Cells are intelligent.” The cells organize themselves into functioning liver tissue with little human direction. The underlying mechanisms are still not fully understood (27:50–29:47).
• Beyond the Liver
  • The same platform may allow for pancreas, thymus, or kidney regeneration in the future.

6. Challenges and Unknowns

• Immune Rejection
  • As donor cells are used, patients require immunosuppression. Acute rejection is a concern, especially with relatively small numbers of cells (32:05).
  • Jacob Goldstein: “What if you took some of their own liver cells and put them in the lymph node? You wouldn't have the rejection problem.”
    Dr. Hufford: “For end stage disease, biopsying [liver] carries catastrophic bleeding risk.” (33:10)
• Future Potential: Stem Cells
  • The vision is to eventually use patients’ own cells, possibly via induced pluripotent stem cell (iPSC) technology. However, no one has yet succeeded in creating mature human hepatocytes this way (33:42–34:21).
• Procedural Risks and Business Risks
  • Endoscopic techniques are familiar but not risk-free.
  • As with any biotech startup, funding and capital efficiency are ongoing concerns, but LyGenesis has relied on efficient NIH funding and a lean company structure to date (35:19–37:11).

7. Broader Impact and the Future of Regenerative Medicine

• Hope for the End of Transplant Waiting Lists
  • “I think in 10 years there is the realistic possibility that at least in some cases, like a liver transplant, those [waiting lists] are relegated to medical history books…” (38:00)
  • The technology could pave the way for patients to become “the source of [their] own medicine.”
• Lightning Round on Personal and Broader Insights (42:27)
  • Dr. Hufford reflects on skills from being a psychologist, harm reduction work making naloxone (opioid overdose antidote) affordable, and balancing family, health, and hobbies as a startup founder.

Notable Quotes & Memorable Moments

• On the Promise of LyGenesis’ Approach
  “You have to use very powerful drugs to try to convince [the body] not to reject those cells. And so I think acute rejection, especially when you're injecting a relatively small number of cells as compared to a very large organ, I think that's one thing that you worry about.” — Michael Hufford (32:05)

• On the Unknowns in Science
  “The short answer is we don’t know. The longer answer is, yeah, well… The cells are remarkably intelligent.” — Michael Hufford (29:15)

• On the Potential Social Impact
  “Bumping up functional liver by 10 to 20%... could be transformative.” (23:06)

• On Funding and Startups
  “I was told a long time ago that the definition of a biotech is a company unencumbered with revenues.”— Michael Hufford (35:32)

• On the Future of Organ Transplants
  “I think there's this opportunity that… in the really foreseeable future, you're going to be the source of your own medicine.” — Michael Hufford (38:00)

Timestamps for Key Segments

• [03:50] – The regenerative power of the liver and a nod to Greek mythology.
• [06:14] – Limits of liver transplantation and why new therapies are needed.
• [09:47] – The discovery that liver cells can regenerate functional mini-livers in lymph nodes.
• [13:58] – Preclinical success in large animals (pigs).
• [16:09] – Details on current human clinical trials and how patients are selected.
• [19:24] – Step-by-step description of the transplantation procedure.
• [23:06] – How much new liver function is needed to help patients.
• [27:50] – The concept of “intelligent cells” and self-organization.
• [30:26] – The versatility and potential future uses of the lymph node platform.
• [32:05] – Medical and immunological risks facing the therapy.
• [35:32] – Business risks and managing a biotech startup.
• [38:00] – The future: potential end of transplant waiting lists.
• [42:27] – Lightning round: Hufford's background, addiction science, harm reduction, and personal life balance.

Final Thoughts

This episode offers an exciting glimpse into a potential revolution in medicine—one that could save countless lives by circumventing both the shortage and the trauma of current organ transplantation. It illustrates the power of combining academic discovery, entrepreneurial drive, and efficient use of resources to push medical frontiers forward. Dr. Hufford’s optimism is tempered by reality, but his vision—of a world where growing new organs is routine—is both vivid and contagious.

For listeners interested in science, biotech, or the future of medicine, this episode provides a hopeful and deeply informative narrative on how innovation can tackle one of healthcare’s biggest challenges.